COSM earnings analysis
What we found in COSM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment data, or MD&A, so current-quarter revenue, margins, EPS, cash flow, and quantitative guidance cannot be assessed. The principal disclosed development is a high-risk control environment: management concluded disclosure controls were ineffective because of 2 material weaknesses. Remediation is underway with a third-party consultant, but its evaluation remained ongoing and the final report had not been received as of August 18, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Control Remediation Underway
- Management states that a third-party consultant has been engaged to assist with control design, implementation, and gap evaluation; the consultant’s final report had not yet been received as of the filing date.
- Independent Audit Committee
- The Audit Committee consists of 3 independent directors: Anastasios Aslidis, John Hoidas, and Demetrios Demetriades.
- Formal Audit Oversight
- The Audit Committee is required to meet no less frequently than 4 times per year, with additional meetings as circumstances warrant.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective Disclosure Controls
- Management concluded that disclosure controls and procedures were ineffective as of the period end because of 2 identified weaknesses: inadequate supervision and segregation of duties, and ineffective IT general controls covering incompatible duties, program changes, and user access.
- IT General Control Deficiencies
- The IT control weakness includes 3 specific areas—segregation of incompatible duties, program change management, and user access controls—raising the risk of inaccurate or delayed financial reporting until remediation is validated.
- Remediation Status Unresolved
- Remediation is not complete: the consultant’s evaluation remained ongoing and no final report had been received as of the August 18, 2026 filing date. Management also states that successful remediation requires review and evidence of effectiveness before concluding that controls are effective.
What they said about what is next.
The supplied filing extract contains no MD&A, quantitative outlook, or explicit revenue/EPS guidance. Financial statement and guidance data were not available in the provided text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 20, 2026
- Cosmos Health reported a substantial revenue increase of 30.7% year-over-year for Q1 2026, reaching $17,927,892, although they experienced a significant net loss of $2,805,423, indicating ongoing challenges in…
- 10-K · April 15, 2026
- Cosmos Health describes a vertically integrated healthcare model combining generics, nutraceuticals, manufacturing, distribution, telehealth (ZipDoctor) and an AI drug‑repurposing platform (Cloudscreen). The filing…
- 10-Q · August 18, 2025
- Cosmos Health reported Q2 revenue of $14,745,702 (up from $13,206,717 in Q2 2024) with gross profit of $1,163,814 and a quarterly net loss of $2,828,068 (basic/diluted loss per share $0.10). Gross margin improved to…
- 10-K · April 15, 2025
- Cosmos Health presents a vertically integrated healthcare model spanning generics, nutraceuticals (≈165 SKUs), biocides, manufacturing/CMO services, telehealth (ZipDoctor) and an AI drug‑repurposing platform…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing COSM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever